ESTRO 2024 - Abstract Book

S87

Invited Speaker

ESTRO 2024

Quality checks that enable the clinical use of synthetic CT

Fernanda Villegas-Navarro

Karolinska University Hospital, Radiotherapy Physics and Engineering, Stockholm, Sweden. Karolinska Institutet, Oncology-Pathology, Stockholm, Sweden

Abstract:

The interest for using a synthetic CT (sCT) generated from magnetic resonance imaging (MRI), instead of the radiotherapy (RT) planning computed tomography (pCT) has increased in the last few years; particularly for AI-based sCT solutions as they have demonstrated very promising results in terms of image quality and dose calculation performance for challenging anatomical sites. However, the lack of international consensus on quality assurance (QA) for sCT has hindered the clinical implementation of MR-only RT workflows. Indeed, only a handful of hospitals have published their experiences on adopting this type of workflow; reporting different approaches depending on the anatomical site and type of sCT algorithm used to replace the pCT. As a first move towards QA consensus, a group of sCT developers and users gathered at the 2022 ESTRO Physics Workshop on the topic “Next generation MR-guided radiotherapy: AI applications for planning and image guidance” to discuss experiences on the integration of AI-generated sCT in the clinic, highlighting key aspects that could be generalized during implementation processes. Thus, this talk will outline some of these discussion points giving the current position on the clinical field. Particularly, it will focus on the aspects of: machine QA – existing recommendations on MR QA and relevant elements for ensuring the right level of image quality of the sCT required for radiotherapy; and MR-only workflow testing – key aspects of an RT workflow that are influenced by the transition from pCT to sCT and that could be considered as part of the QA protocol. It is the hope that this work will encourage the clinical community to conduct further prospective studies with a standardized reporting system. This would facilitate reaching a consensus on key image quality and dosimetric metrics. Finally, the vendor community is also encouraged to develop sCT QA tools that would ensure safe usage and sustainability of the sCT solutions.

3470

Quality of life and cosmetic assessment in skin cancer treatment

Vassilios Vassiliou

Bank of Cyprus Oncology Centre, Radiation Oncology, Nicosia, Cyprus

Abstract:

Quality of life (QoL) and cosmetic assessment in skin cancer treatment

Basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (SCC) are collectively known as keratinocyte carcinomas (KC). They are the most prevalent malignancy with an increasing incidence, mainly resulting from the aging population and Ultraviolet radiation exposure. In the USA 5.4 million KC cases are diagnosed per year, whereas in Europe 356.000 new cases were diagnosed in 2020.